Somatic Tests
Somatic genetic/genomic tests in cancer are typically performed on tumor tissue (FFPE block/Fresh tissue) to identify somatic mutations, which might help identify the clinically actionable genomic alterations for cancer patients. Our TARGT (Tumor-Associated Drug Response by Genomic Testing) portfolio of genetic/genomic tests is validated to identify somatic mutations in the tumor tissue with high sensitivity and specificity to detect even low-frequency genomic alterations/aberrations/mutations that drive cancer.All the tests under the TARGT portfolio identify genetic variants associated with approved treatment and clinical trials. TARGT tests report actionable and targetable somatic mutations, which include SNVs, Indels, CNAs, and Genomic Signatures like Tumor Mutational Burden (TMB) and Microsatellite Instability (MSI).
Click on the below icons to know more about our Somatic Tests
Hereditary Cancer Test
Genetic variations/mutations/aberrations in the genes you are born with can increase your cancer risk. Our NGS (Next-Generation Sequencing) based Hereditary Cancer genetic test - Germline+ analyses 213 genes associated with cancer risk DDR (DNA Damage Repair) and HRR (Homologous Recombination Repair) pathway. The panel includes genes associated with familial and hereditary cancers (Breast, Ovarian, Prostate, Pancreatic, etc).As per ACMG guidelines, the detected variants are classified as: pathogenic, likely pathogenic, VUS, likely benign, and benign. This may attribute to a high, moderate, or low risk of getting cancer.
Some of the Germline variants like in the BRCA gene not just help in identifying cancer risk but also help in making PARP (Poly-ADP-Ribose Polymerase) inhibitor targeted therapy treatment decisions.
Click on the below icon to know more about our Hereditary Cancer Test
Liquid Biopsy Assay
Liquid biopsy is a minimally invasive blood-based assay that has a role in diagnostic, and prognostic as well as therapeutic treatment-related decisions for cancer patients.The assay isolates and detects tumor genomes and associated genomic alterations such as SNVs/InDels, CNAs, and Gene Fusions from peripheral blood.
Liquid biopsies have been recognized as a valuable diagnostic and monitoring tool. With FDA approving the use of liquid biopsies for Non-Small Cell Lung Cancer and other solid tumors, oncologists around the globe are utilizing this technique for various cancer patients.
The technique of liquid biopsy involves drawing blood from the cancer patient and analyzing the presence of tumor or tumor content in the bloodstream. When compared to tissue biopsies, liquid biopsies are quicker, easier, less painful, and are considered to be minimally invasive as it requires only drawing of blood from the patient. The technique involves extracting tumor DNA from blood followed by NGS analysis for precise cancer management.
Click on the below icon to know more about our Liquid Biopsy Assay